Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma

Tumori. 1983 Aug 31;69(4):323-6. doi: 10.1177/030089168306900408.

Abstract

From May 1980 to November 1981, 51 consecutive patients with locally advanced, recurrent or metastatic head and neck squamous carcinoma were treated with 2 successive outpatient chemotherapeutic regimens including adriamycin, cyclophosphamide, vincristine, bleomycin, methotrexate and 5-fluorouracil with or without mitomycin-C. A 34% objective response rate was obtained with acceptable toxicity and good patient compliance. The presence of mitomycin-C did not influence response rate. Median survival was 9 months.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / secondary
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Fluorouracil / administration & dosage
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / secondary
  • Humans
  • Methotrexate / administration & dosage
  • Mitomycin
  • Mitomycins / administration & dosage
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Time Factors
  • Vincristine / administration & dosage

Substances

  • Mitomycins
  • Bleomycin
  • Mitomycin
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate